Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Overcome with the Addition of Uproleselan

Daniel J. DeAngelo, MD PhD, Brian A Jonas, MD PhD, Jane L. Liesveld, MD, Dale L. Bixby, MD, Anjali S. Advani, MD, Paula Marlton, MBBS (Hons), FRACP, FRCPA, Michael E O'Dwyer, MD, William E. Fogler, PhD, John L. Magnani, PhD, Mary M Chen, MD PhD, Eric J. Feldman, MD, Helen M Thackray, MD, Pamela S. Becker, MD PhD

Blood (2019) 134 (Supplement_1): 2690.

https://doi.org/10.1182/blood-2019-123744

Published: 2019

Journal Articles

A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia

Daniel J. DeAngelo, MD PhD, Harry P. Erba, MD PhD, Brian A Jonas, MD PhD, Michael E O'Dwyer, MD, Paula Marlton, MBBS (Hons), FRACP, FRCPA, Gerwin Huls, MD PhD, Jane L. Liesveld, MD, Brenda Cooper, MD, Bhavana Bhatnagar, DO, Geoffrey L. Uy, MD, Gavin Cull, MB, BS, FRACP, FRCPA, Michael B. Armstrong, MD PhD, William E. Fogler, PhD, Mary M Chen, MD PhD, John L. Magnani, PhD, Helen M Thackray, MD, Eric J. Feldman, MD, Anjali S. Advani, MD, Pamela S. Becker, MD PhD

Blood (2019) 134 (Supplement_1): 2650.

https://doi.org/10.1182/blood-2019-123816

Published: 2019

Journal Articles

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2x2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Peter Westervelt, MDPhD, Gail J. Roboz, MD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Sangmin Lee, MD, Michael P. Rettig, PhD, Tae H. Han, PhD, Jeanmarie Guenot, PhD, Eric J. Feldman, MD, John F. DiPersio, MD PhD

Blood (2018) 132 (Supplement 1): 1455.

https://doi.org/10.1182/blood-2018-99-111529

Published: 2018

Journal Articles

A Phase 1b Study of Vadastuximab Talirine As Maintenance and in Combination with Standard Consolidation for Patients with Acute Myeloid Leukemia (AML)

Jay Yang, MD, Farhad Ravandi, MD, Anjali Advani, MD, Sumithira Vasu, MBBS, Roland B. Walter, MD PhD, Stefan Faderl, MD, Anthony S. Stein, MD, Harry P. Erba, MD PhD, Amir T. Fathi, MD, William B. Donnellan, MD, Moshe Y Levy, MD, Scott E. Smith, MD PhD, Brent L. Wood, MD PhD, Eric J. Feldman, MD, Jenna L Voellinger, PhD, Michael B. Maris, MD

Blood (2016) 128 (22): 340.

https://doi.org/10.1182/blood.V128.22.340.340

Published: 2016

Journal Articles

A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Harry P. Erba, MD PhD, Moshe Y Levy, MD, Sumithira Vasu, MBBS, Anthony S. Stein, MD, Amir T. Fathi, MD, Michael B. Maris, MD, Anjali Advani, MD, Stefan Faderl, MD, Scott E. Smith, MD PhD, Brent L. Wood, MD PhD, Roland B. Walter, MD PhD, Jay Yang, MD, William B. Donnellan, MD, Eric J. Feldman, MD, Jenna L Voellinger, PhD, Farhad Ravandi, MD

Blood (2016) 128 (22): 211.

https://doi.org/10.1182/blood.V128.22.211.211

Published: 2016

Journal Articles

SGN-CD33A in Combination with Hypomethylating Agents Is Highly Efficacious in Preclinical Models of AML

May S.K. Sutherland, PhD, Changpu Yu, Christine O'Day, PhD, Steve Alley, PhD, Martha Anderson, Kim Emmerton, Weipeng Zeng, Megan M. O'Meara, MD, Eric J. Feldman, MD, Dana A. Kennedy, Maureen C. Ryan, PhD, Dennis Benjamin, PhD

Blood (2015) 126 (23): 3785.

https://doi.org/10.1182/blood.V126.23.3785.3785

Published: 2015

Journal Articles

In Vivo Treatment with TG-02 Results in Increased Mobilization and Sensitization of Leukemia Stem Cells to Chemotherapeutic Agents

Zeena Salman, MD MPH, Jeanne P. De Leon, Eric J. Feldman, MD, Francis Burrows, PhD, Gail J. Roboz, MD, Monica L. Guzman, PhD

Blood (2014) 124 (21): 3765.

https://doi.org/10.1182/blood.V124.21.3765.3765

Published: 2014

Journal Articles

Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR)

Blood (2014) 124 (21): LBA-6.

https://doi.org/10.1182/blood.V124.21.LBA-6.LBA-6

Published: 2014

Journal Articles

Comprehensive Geriatric Assessment Does Not Predict Overall Survival in Older Patients with Acute Myeloid Leukemia (AML)

Ellen K. Ritchie, MD, Danielle C. Marshall, B.A., Molly D. Greenberg, B.S., Tania J. Curcio, R.N, Ashley E. Giambrone, PhD, Paul Christos, DrPH, Eric J. Feldman, MD, Joseph M. Scandura, MD PhD, Gail J. Roboz, MD

Blood (2014) 124 (21): 3689.

https://doi.org/10.1182/blood.V124.21.3689.3689

Published: 2014

Journal Articles

Arterial Thrombotic Complications Are Uncommon in Patients without Cardiovascular Risk Factors and Occur at Equivalent Rates in Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib and Nilotinib

Hesam Hekmatjou, MD, Gail J. Roboz, MD, Ellen K. Ritchie, MD, Sangmin Lee, MD, Pinkal Desai, MD, Joseph M. Scandura, MD PhD, Sandra Allen-Bard, ANP, BS, BSN, MSN, NP, Paul Christos, DrPH, Richard T. Silver, MD, Eric J. Feldman, MD

Blood (2014) 124 (21): 1811.

https://doi.org/10.1182/blood.V124.21.1811.1811

Published: 2014

Journal Articles

Interleukin 2 Receptor-α (CD25) Expression Is Associated with Shortened Overall Survival and Resistance to Induction Therapy with Plerixafor and Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

John N. Allan, MD, Gail J. Roboz, MD, Eric J. Feldman, MD, Joseph M. Scandura, MD PhD, Ellen K. Ritchie, MD, Linda Lam, Wen Xie, Hsiao-Ting Hsu, MS, Duane C Hassane, PhD, Monica L. Guzman, PhD

Blood (2014) 124 (21): 1041.

https://doi.org/10.1182/blood.V124.21.1041.1041

Published: 2014

Journal Articles

Recombinant Interferon Alpha (rIFN) May Retard Progression Of Early Myelofibrosis By Reducing Splenomegaly and By Decreasing Marrow Fibrosis

Richard T. Silver, Elena Lascu, Eric J. Feldman, MD, Ellen Ritchie, MD, Gail J. Roboz, MD, Maria Teresa De Sancho, MD, MSc, Ruth Bauman, Attilio Orazi, MD

Blood (2013) 122 (21): 4053.

https://doi.org/10.1182/blood.V122.21.4053.4053

Published: 2013

Journal Articles

Leukemia Stem/Progenitor Cells From AML Patients Treated With The Multi-Kinase Inhibitor TG02 Demonstrate Increased Proliferation and Are Sensitized To Chemotherapeutic Agents

Monica L. Guzman, PhD, Wen Xie, MS, Jeanne P. De Leon, Francis Burrows, PhD, Eric J. Feldman, MD, Gail J. Roboz, MD

Blood (2013) 122 (21): 3892.

https://doi.org/10.1182/blood.V122.21.3892.3892

Published: 2013

Journal Articles

A Phase II Trial Of Epigenetic Modulators Vorinostat In Combination With Azacitidine (azaC) In Patients With The Myelodysplastic Syndrome (MDS): Initial Results Of Study 6898 Of The New York Cancer Consortium

Lewis R. Silverman, MD, Amit Verma, MD, Rosalie Odchimar-Reissig, RN, Eric J. Feldman, MD, Shyamala C. Navada, MD, Erin P Demakos, RN, Maria R. Baer, MD, Vesna Najfeld, PhD, Joseph A Sparano, MD, Richard Piekarz, MD, PhD

Blood (2013) 122 (21): 386.

https://doi.org/10.1182/blood.V122.21.386.386

Published: 2013

Journal Articles

DNA Demethylation Activity Over Time and Safety Of 3 Different Dose-Escalation Regimens Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In The Treatment Of Relapsed/Refractory Patients With MDS and AML

Blood (2013) 122 (21): 1548.

https://doi.org/10.1182/blood.V122.21.1548.1548

Published: 2013

Journal Articles

Combining Decitabine With Plerixafor Yields a High Response Rate In Newly Diagnosed Older Patients With AML

Gail J. Roboz, MD, Joseph M. Scandura, MD, PhD, Ellen Ritchie, MD, Yulia Dault, RN, Linda Lam, Wen Xie, Hsiao-Ting Hsu, Danielle Marshall, Paul J Christos, Cindy Ippoliti, Eric J. Feldman, MD, Monica L. Guzman, PhD

Blood (2013) 122 (21): 621.

https://doi.org/10.1182/blood.V122.21.621.621

Published: 2013

Journal Articles

First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In Adult Patients With Acute Myeloid Leukemia (AML)

Blood (2013) 122 (21): 497.

https://doi.org/10.1182/blood.V122.21.497.497

Published: 2013

Journal Articles

A Phase 1 Study of Bendamustine and Melphalan Conditioning for Autologous Stem Cell Transplant in Multiple Myeloma

Tomer M Mark, MD, MSc, Whitney Reid, Ruben Niesvizky, MD, Usama Gergis, MD, Roger N Pearse, MD, PhD, Sebastian Mayer, MD, Morton Coleman, MD, Eric J Feldman, MD, Tsiporah B. Shore, MD

Blood (2011) 118 (21): 2042.

https://doi.org/10.1182/blood.V118.21.2042.2042

Published: 2011

Journal Articles

Significance of Prior HSCT on the Outcome of Salvage Therapy with CPX-351 or Conventional Chemotherapy Among First Relapse AML Patients

Jorge E. Cortes, Eric J Feldman, MD, Stuart L. Goldberg, MD, David A. Rizzieri, MD, Arthur C. Louie, MD, Jonathan E. Kolitz, MD

Blood (2011) 118 (21): 2619.

https://doi.org/10.1182/blood.V118.21.2619.2619

Published: 2011

Journal Articles

Results of the OPAL Study: A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of Tosedostat (CHR-2797) in Elderly Subjects with Treatment Refractory or Relapsed Acute Myeloid Leukemia

Jorge E. Cortes, Eric J Feldman, MD, Karen Yee, MD, David A. Rizzieri, MD, Anjali S. Advani, MD, Anthony Charman, PhD, Martin J. Toal, FFPM, Hagop M. Kantarjian

Blood (2011) 118 (21): 767.

https://doi.org/10.1182/blood.V118.21.767.767

Published: 2011

NARROW

High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Overcome with the Addition of Uproleselan

A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2x2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

A Phase 1b Study of Vadastuximab Talirine As Maintenance and in Combination with Standard Consolidation for Patients with Acute Myeloid Leukemia (AML)

A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

SGN-CD33A in Combination with Hypomethylating Agents Is Highly Efficacious in Preclinical Models of AML

In Vivo Treatment with TG-02 Results in Increased Mobilization and Sensitization of Leukemia Stem Cells to Chemotherapeutic Agents

Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR)

Comprehensive Geriatric Assessment Does Not Predict Overall Survival in Older Patients with Acute Myeloid Leukemia (AML)

Arterial Thrombotic Complications Are Uncommon in Patients without Cardiovascular Risk Factors and Occur at Equivalent Rates in Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib and Nilotinib

Interleukin 2 Receptor-α (CD25) Expression Is Associated with Shortened Overall Survival and Resistance to Induction Therapy with Plerixafor and Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Recombinant Interferon Alpha (rIFN) May Retard Progression Of Early Myelofibrosis By Reducing Splenomegaly and By Decreasing Marrow Fibrosis

Leukemia Stem/Progenitor Cells From AML Patients Treated With The Multi-Kinase Inhibitor TG02 Demonstrate Increased Proliferation and Are Sensitized To Chemotherapeutic Agents

A Phase II Trial Of Epigenetic Modulators Vorinostat In Combination With Azacitidine (azaC) In Patients With The Myelodysplastic Syndrome (MDS): Initial Results Of Study 6898 Of The New York Cancer Consortium

DNA Demethylation Activity Over Time and Safety Of 3 Different Dose-Escalation Regimens Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In The Treatment Of Relapsed/Refractory Patients With MDS and AML

Combining Decitabine With Plerixafor Yields a High Response Rate In Newly Diagnosed Older Patients With AML

First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In Adult Patients With Acute Myeloid Leukemia (AML)

A Phase 1 Study of Bendamustine and Melphalan Conditioning for Autologous Stem Cell Transplant in Multiple Myeloma

Significance of Prior HSCT on the Outcome of Salvage Therapy with CPX-351 or Conventional Chemotherapy Among First Relapse AML Patients

Results of the OPAL Study: A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of Tosedostat (CHR-2797) in Elderly Subjects with Treatment Refractory or Relapsed Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only